Canaccord analyst Kyle Mikson raised the firm’s price target on Guardant Health (GH) to $60 from $42 and keeps a Buy rating on the shares. The firm said they remain bullish after a strong finish to 2024 and solid outlook for 2025 with multiplepotential catalysts. They raise their target on higher margins in their discount free cash flow due to average sellng price tailwinds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health: Positioned for Growth with Shield CRC and Strategic Market Advantages
- Guardant Health Projects Strong Growth Amid Challenges
- Guardant Health sees FY25 revenue $850M-$860M, consensus $853.98M
- Guardant Health reports Q4 adjusted EPS (62c), consensus (74c)
- Guardant Health price target raised to $53 from $45 at Stifel